News & Events about Adicet Bio Inc.
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January 31, 2023. Six individuals hired by Adicet in January 2023 received, in the aggregate...
Shares of Adicet Bio, Inc. (NASDAQ:ACET Get Rating) have been assigned an average recommendation of Moderate Buy from the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and ...
Adicet Bio, Inc. (NASDAQ:ACET Get Rating) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 4,020,000 shares, an increase of 29.7% from the November 15th total of 3,100,000 shares. Approximately...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data from the Companys ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or...
Business Wire
2 months ago
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut...